Barrington Research Has Pessimistic View of MMSI Q2 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Equities research analysts at Barrington Research lowered their Q2 2025 earnings per share estimates for Merit Medical Systems in a research note issued to investors on Thursday, October 31st. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will earn $1.05 per share for the quarter, down from their prior forecast of $1.06. Barrington Research currently has a “Outperform” rating and a $114.00 target price on the stock. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share. Barrington Research also issued estimates for Merit Medical Systems’ Q3 2025 earnings at $0.95 EPS, Q4 2025 earnings at $0.92 EPS, FY2025 earnings at $3.80 EPS and FY2026 earnings at $4.25 EPS.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings data on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.06. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The firm had revenue of $339.85 million during the quarter, compared to the consensus estimate of $334.60 million. During the same period in the prior year, the business earned $0.75 EPS. The business’s revenue for the quarter was up 7.8% on a year-over-year basis.

A number of other equities research analysts also recently issued reports on MMSI. Needham & Company LLC reiterated a “buy” rating and issued a $109.00 target price on shares of Merit Medical Systems in a research report on Thursday, October 31st. Wells Fargo & Company upped their price target on shares of Merit Medical Systems from $85.00 to $103.00 and gave the stock an “equal weight” rating in a research note on Monday, September 16th. Piper Sandler reissued an “overweight” rating and set a $110.00 price objective (up previously from $100.00) on shares of Merit Medical Systems in a research report on Monday, September 9th. StockNews.com lowered Merit Medical Systems from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Bank of America raised their price target on Merit Medical Systems from $92.00 to $103.00 and gave the stock a “neutral” rating in a research note on Monday, September 16th. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Merit Medical Systems presently has an average rating of “Moderate Buy” and a consensus price target of $103.36.

Merit Medical Systems Price Performance

NASDAQ MMSI opened at $99.08 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 4.64. The firm has a market capitalization of $5.77 billion, a price-to-earnings ratio of 48.57, a price-to-earnings-growth ratio of 2.45 and a beta of 0.89. The company has a 50 day simple moving average of $96.72 and a 200-day simple moving average of $88.31. Merit Medical Systems has a 52-week low of $65.46 and a 52-week high of $101.60.

Institutional Investors Weigh In On Merit Medical Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. UniSuper Management Pty Ltd acquired a new stake in shares of Merit Medical Systems in the first quarter worth $1,083,000. Quantbot Technologies LP lifted its position in Merit Medical Systems by 17,716.1% during the 1st quarter. Quantbot Technologies LP now owns 9,977 shares of the medical instruments supplier’s stock worth $756,000 after acquiring an additional 9,921 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in Merit Medical Systems by 36.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 22,144 shares of the medical instruments supplier’s stock valued at $1,638,000 after acquiring an additional 5,915 shares during the period. BNP Paribas Financial Markets grew its position in shares of Merit Medical Systems by 55.3% in the first quarter. BNP Paribas Financial Markets now owns 52,953 shares of the medical instruments supplier’s stock valued at $4,011,000 after purchasing an additional 18,863 shares during the last quarter. Finally, Lazard Asset Management LLC increased its stake in shares of Merit Medical Systems by 1,147.3% in the first quarter. Lazard Asset Management LLC now owns 7,858 shares of the medical instruments supplier’s stock worth $594,000 after purchasing an additional 7,228 shares during the period. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.